Acquisition of Applied Pharma Research (‘APR’) by RELIEF THERAPEUTICS

IndustryLife Sciences

BDO provided M&A buy-side support and commercial due diligence to RELIEF THERAPEUTICS Holding AG.

RELIEF THERAPEUTICS is a biopharmaceutical company listed on Swiss stock exchange, focusing on providing medicines to patients with serious diseases and high unmet need. The APR acquisition is an important milestone in Relief’s transformation into a fully integrated diversified commercial-stage pharmaceutical company. It adds a pipeline of commercial products and clinical-stage programmes and provides a commercial infrastructure for future product launches.

"The BDO team did an excellent job providing valuable buy-side support and project management of the due diligence process through to completion of our acquisition of APR, a Swiss based pharmaceutical company.

BDO also provided an excellent commercial Due Diligence report on the APR portfolio and its commercial capabilities, leveraging their knowledge of the pharmaceutical sector.

It was a pleasure working with the highly responsive BDO team. Without the BDO support meeting tight deadlines would not have been possible."

Raghuram (Ram) Selvaraju, Chairman of the Board of Relief